TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Functional Connectivity Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Erythema Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Telangiectasia Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of enrolled patients per year with adequate clinicopathologically annotated biological material and clinical data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Cmax (Tmax) Following IV Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reduction of direct bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in ASES elbow score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Tedizolid
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Tedizolid
Endpoint domain: Adverse events/effects
Primary endpoint: Level of anxiety difference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spatial Stability of Lung Perfusion and Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Sensitivity and Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing a Device Related SAE (SADE) and Complications During Implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Intraclass Correlation Between Intraocular Pressure (IOP) Measurements by GAT and the ARGOS-IO System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Developing New Grade >=3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Classified as Responders as Measured by Serum Anti-rotavirus IgA ELISA and Serum Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Days With at Least Moderate Common Cold Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability as assessed by Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: clinically significant change from baseline in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant change from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Magnitude of Yellow Fever Virus (YFV) specific T Cell Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Quality of YFV-specific T Cell Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Magnitude of YFV-specific Antibody Secreting Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Collection of brown adipose neck tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 6 Minute Walking Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CHEOPS Score Measured Level of Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC - pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cancer-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence of Lassa virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of individuals with symptoms consistent with Lassa fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Annual incidence of seroconversion due to Lassa virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effectiveness of the safety lancet's sharps injury prevention features
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Reynolds Adolescent Depression Scale (RADS-2) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral blood perfusion (CBP) in the anterior cingulate cortex (ACC)- striato - amygdalo - thalamic network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Combined Unique Active Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hair regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum BNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Brief Pain inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allelic frequency and type of myeloid cancer-associated mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occult and clinically significant CAD detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between myeloid mutations and CAD presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of revision surgery at the treated level
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in degree of disability as measured by the Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in back pain as measured by 10-centimeter Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amount of drainage from skin closure site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Identification of functional defects in Fanconi anemia hematopoietic stromal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to and incidence of biopsy-proven acute rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Culture conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Oxygenation (StO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue-Hemoglobin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Infrared Perfusion Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue-Water-Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving Blood Pressure Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful repair at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety as Determined by Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sweat Chloride From Baseline Through Study Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Patient Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of teriflunomide in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Suppressors After Dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change scores of Mini-Mental State Exam (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of the Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Functional Independence Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in paediatric IBD-specific health-related quality of life (QOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Emergency Room Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Displacement of sub macular hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Level of pain experienced at the time of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain experienced from time of surgery to 8 weeks after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve bi-directional block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of therapeutic paracenteses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of miscarriages
Endpoint domain: Mortality/survival
Primary endpoint: Change of load of traumatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of number of aggressive acts
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change of experienced parental maltreatment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Amputation free survival
Endpoint domain: Mortality/survival
Primary endpoint: Maximal blood alcohol concentration (BAC Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comprehensive ability evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pre-procedure Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Post-procedure Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-week Post-procedure Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Subjects With Composite Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spinal Cord Injury Independence Measure - Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper and Lower Extremity Strength by a manual muscle test (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of life and health measured by the WHOQOL-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of interventional cryoablation
Endpoint domain: Adverse events/effects
Primary endpoint: Cup Orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's understanding of health disparities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Leadership and health advocacy skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Interest in health-related careers
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Ratio of S2-stage transition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of participants who report having tested for HIV twice in the past 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean percentage of PrEP-eligible participants who report having consulted with a provider about PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean percentage of participants who report having had unprotected sex with a casual partner
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percentage of participants who report having tested for HIV in the past 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC0-Inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time to Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Residents performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA Heart Failure class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Being Very Satisfied or Somewhat Satisfied With the Program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sum of Pain Intensity Difference Over 12 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Alive and Without Disease Progression At 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility for Patient Enrollment and Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline of gastrointestinal symptom VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Participant satisfaction with virtual simulations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pre and post test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of organ preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Tumor Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Relapse-free Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pelvic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean Difference in Quality Adjusted Life Years (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anti-AMG 282 antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemia-driven target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of CRC by EMT-TF mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision change in treatment recommendation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cytokine levels in blood, bronchial lavage fluid and pleural fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between cytokine levels and pulmonary morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in end tidal CO2 in mmHg (EtCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in oxygen saturation (SO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response After Induction Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Local Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Infusion Set Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Perceived Stress score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in General Life Satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Positive Affect score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent days abstinence from substances
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality within Emergency department
Endpoint domain: Mortality/survival
Primary endpoint: Relative rate of virtual lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Cancer Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: change in esophageal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Serum Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Hierarchical Composite of Stroke, Myocardial Infarction, and Death
Endpoint domain: Mortality/survival
Primary endpoint: Thigh perimeter measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Amplitude of Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive and Negative Symptoms Scale (PANSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of the experimental drug
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking cessation/abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle and body fat distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hours fasted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent calorie and fat-gram compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Relapse
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intent to talk to a physician about smoking cessation study participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in serum calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of suboptimal prescribing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: breast cancer recurrence-free interval (BCRFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 3 and above mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Subjects With Antigenically Matched Strain-specific Hemagglutination Inhibition (HAI) Seroconversion Following the First Dose - H1N1 /wt A/New Caledonia/20/99 Influenza Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Antigenically Matched Strain-specific Hemagglutination Inhibition (HAI) Seroconversion Following the Second Dose - H1N1 /wt A/New Caledonia/20/99 Influenza Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemagglutination Inhibition (HAI) Geometric Mean Titers (GMTs) in Baseline Seronegative Subjects Following the First Dose - H1N1 /wt A/New Caledonia/20/99 Influenza Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain Derived Neurotrophic Factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distance immediately post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with arrythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PA-VAP recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of fibromyalgia subjects maintaining clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Percentile at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of resting ECG abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma levels of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensorimotor outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes